Protagonist has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under our worldwide license and collaboration agreement with Takeda for rusfertide, an investigational first-in-class hepcidin mimetic peptide. Rusfertide is now under U.S. Food and Drug Administration (FDA) Priority Review for the treatment of adults with polycythemia vera (PV). Read more: accessnewswire.com/newsroom/…

What a week for all of us at Protagonist! After celebrating the FDA Approval of ICOTYDE, we are thrilled to be recognized on the Nasdaq Tower in Times Square as a Fast 500 company. Ranking among the fastest-growing innovative companies in North America is a powerful validation of our innovation platform. To our customers, partners, and every member of the Protagonist family: This moment belongs to you. We’re just getting started. Looking forward to what's yet to come. #PTGX #NASDAQ #BayAreaFast500 #Biotech #Innovation

Proud moment for Protagonist Therapeutics: today’s FDA approval of ICOTYDE marks 13 years of scientific dedication and operational excellence. A testament to our peptide platform and collaboration with Johnson & Johnson. Grateful to all who made this possible.

Today the FDA approved ICOTYDE™ (icotrokinra), the first targeted oral peptide option for first-line systemic treatment of plaque psoriasis. This milestone reflects the power of our science and platform. Thank you to the PTGX team, Johnson & Johnson, investigators and patients who made it possible. Read more: bit.ly/4sckfLP

Today, Protagonist and Takeda announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for rusfertide, an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV). Read more details in our latest press release: feeds.issuerdirect.com/news-…

Takeda and Protagonist Therapeutics have announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Read more in our latest press release: bit.ly/4sqgV03

We are pleased to see Protagonist be named a @Citeline 2025 #ScripAwards finalist for “Clinical Advance of the Year” in recognition of the highly positive outcome of the Phase III VERIFY study of rusfertide in polycythemia vera (PV). We are honored to be in the company of other innovative finalists working to advance healthcare. See the shortlist here: citeline.com/en/awards/scrip…

From platform to pipeline to patients. Presentations this week at #EADV2025 will demonstrate the potential of our peptide therapeutic discovery and development platform to redefine standards in psoriasis care. Read more: feeds.issuerdirect.com/news-…

Today, we announced that Johnson & Johnson (@JNJNews) has submitted a Marketing Authorization Application to the European Medicines Agency for icotrokinra, a first‑in‑class investigational oral peptide co-discovered by Protagonist and J&J scientists for adults and adolescents with moderate‑to‑severe plaque #psoriasis. Read more: accessnewswire.com/newsroom/…

News: Protagonist is pleased to announce the submission of a New Drug Application for icotrokinra, the first- and best-in-class oral IL-23R blocker for plaque #psoriasis. Four pivotal Phase 3 ICONIC studies back its potential to transform care and expand across IL-23–mediated diseases. Read more: bit.ly/4nQ8YyW

Today, we hosted a conference call and webcast on our oral obesity development candidate, PN-477. IND-enabling studies are underway, with Phase I study initiation expected in the second quarter of 2026. Read more: bit.ly/4kl5bXj Watch the webcast replay: bit.ly/44nDwiG

After the plenary presentation yesterday at #ASCO25, @ProtagonistCEO Dinesh V. Patel, PhD, had a great conversation with @bradloncar on @BiotechTV about the latest rusfertide data and what's next for Protagonist.